Experimental gene therapy offers hope for rare blindness condition
NCT ID NCT07307469
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study provides ZVS101e, a gene therapy, to 32 people with Bietti crystalline corneoretinal dystrophy (BCD) who were in the control group of a previous Phase III trial. The therapy uses a harmless virus to deliver a working gene to the eye, aiming to slow vision loss. The main goal is to check safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZVS101e (a gene therapy using a harmless virus to deliver a working copy of the CYP4V2 gene into eye cells)
What this could lead to
If it works, this could offer a treatment option for people with Bietti crystalline dystrophy, potentially slowing vision loss.
What could go wrong
This is an early compassionate-use study with only 32 participants, so results may not apply widely. Gene therapies can cause inflammation or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
-
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, China